Pulmonx Co. (NASDAQ:LUNG) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Pulmonx Co. (NASDAQ:LUNG) has received an average rating of “Moderate Buy” from the nine research firms that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $13.36.

A number of brokerages have recently commented on LUNG. Citigroup began coverage on shares of Pulmonx in a report on Monday, March 10th. They issued a “buy” rating on the stock. Jefferies Financial Group initiated coverage on Pulmonx in a research note on Monday, March 10th. They issued a “buy” rating on the stock. Morgan Stanley assumed coverage on Pulmonx in a report on Monday, March 10th. They issued an “equal weight” rating for the company. D. Boral Capital began coverage on Pulmonx in a report on Monday, March 10th. They set a “buy” rating and a $17.00 price objective on the stock. Finally, Wells Fargo & Company dropped their target price on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 11th.

Insider Buying and Selling at Pulmonx

In other Pulmonx news, CEO Steven S. Williamson sold 27,689 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $7.14, for a total value of $197,699.46. Following the completion of the sale, the chief executive officer now owns 194,342 shares in the company, valued at approximately $1,387,601.88. This trade represents a 12.47 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Geoffrey Beran Rose sold 5,779 shares of Pulmonx stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $7.13, for a total value of $41,204.27. Following the completion of the sale, the insider now owns 285,278 shares in the company, valued at approximately $2,034,032.14. This represents a 1.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 147,986 shares of company stock worth $1,143,673. 5.70% of the stock is currently owned by insiders.

Institutional Trading of Pulmonx

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. 272 Capital LP bought a new position in Pulmonx in the 3rd quarter worth $25,000. BNP Paribas Financial Markets purchased a new position in shares of Pulmonx during the fourth quarter valued at about $43,000. R Squared Ltd bought a new position in Pulmonx in the fourth quarter worth about $46,000. ProShare Advisors LLC purchased a new stake in Pulmonx in the fourth quarter worth about $72,000. Finally, Stifel Financial Corp bought a new stake in Pulmonx during the 4th quarter valued at approximately $81,000. Hedge funds and other institutional investors own 91.04% of the company’s stock.

Pulmonx Stock Up 0.7 %

LUNG opened at $6.79 on Friday. The firm has a market capitalization of $270.21 million, a P/E ratio of -4.72 and a beta of 0.50. Pulmonx has a one year low of $5.46 and a one year high of $10.01. The company has a fifty day moving average price of $7.16 and a 200-day moving average price of $6.96. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77.

Pulmonx (NASDAQ:LUNG) last posted its earnings results on Wednesday, February 19th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.12. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. The business had revenue of $23.77 million during the quarter, compared to analysts’ expectations of $22.29 million. Equities research analysts expect that Pulmonx will post -1.55 earnings per share for the current fiscal year.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.